Cargando…

Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance

Lung cancer is treated with many conventional therapies, such as surgery, radiation, and chemotherapy. However, these therapies have multiple undesirable side effects. To bypass the side effects elicited by these conventional treatments, molecularly-targeted therapies are currently in use or under d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schrank, Zachary, Chhabra, Gagan, Lin, Leo, Iderzorig, Tsatsral, Osude, Chike, Khan, Nabiha, Kuckovic, Adijan, Singh, Sanjana, Miller, Rachel J., Puri, Neelu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071023/ https://www.ncbi.nlm.nih.gov/pubmed/29973561 http://dx.doi.org/10.3390/cancers10070224

Ejemplares similares

Oligonucleotides Targeting Telomeres and Telomerase in Cancer
por: Schrank, Zachary, et al.
Publicado: (2018)

Treating Cancer by Targeting Telomeres and Telomerase
por: Ivancich, Marko, et al.
Publicado: (2017)

Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer
por: Osude, Chike, et al.
Publicado: (2022)

Clinical Challenges to Current Molecularly Targeted Therapies in Lung Cancer
por: Chhabra, Gagan, et al.
Publicado: (2015)

Oligonucleotides and microRNAs Targeting Telomerase Subunits in Cancer Therapy
por: Eckburg, Adam, et al.
Publicado: (2020)

Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
por: Botting, Gregory M., et al.
Publicado: (2015)

Resistance to Molecularly Targeted Therapies in Melanoma
por: Patel, Meet, et al.
Publicado: (2021)

PRMT-1 and p120-Catenin as EMT Mediators in Osimertinib Resistance in NSCLC
por: Racherla, Kavya Sri, et al.
Publicado: (2023)

erbB in NSCLC as a molecular target: current evidences and future directions
por: Del Re, Marzia, et al.
Publicado: (2020)

Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer
por: Puri, Neelu, et al.
Publicado: (2008)

Mechanism of DNA damage responses induced by exposure to an oligonucleotide homologous to the telomere overhang in melanoma
por: Pitman, Ryan T, et al.
Publicado: (2013)

Defining molecular risk in ALK(+) NSCLC
por: Christopoulos, Petros, et al.
Publicado: (2019)

Current Approaches in NSCLC Targeting K-RAS and EGFR
por: Aran, Veronica, et al.
Publicado: (2019)

The current treatment landscape in the UK for stage III NSCLC
por: Evison, Matthew
Publicado: (2020)

Targeting ALK Rearrangements in NSCLC: Current State of the Art
por: Peng, Ling, et al.
Publicado: (2022)

Current status and challenges of immunotherapy in ALK rearranged NSCLC
por: Qi, Rongbin, et al.
Publicado: (2022)

Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?
por: Garinet, Simon, et al.
Publicado: (2018)

Radical-Mediated Enzymatic Polymerizations
por: Zavada, Scott R., et al.
Publicado: (2016)

DNA polymerase III α subunit from Mycobacterium tuberculosis H37Rv: Homology modeling and molecular docking of its inhibitor
por: Chhabra, Gagan, et al.
Publicado: (2011)

Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations
por: Chatziandreou, Ilenia, et al.
Publicado: (2015)

Antitumor effect and molecular mechanism of fucoidan in NSCLC
por: Chen, Xiaohan, et al.
Publicado: (2021)

Knockdown of the Fat Mass and Obesity Gene Disrupts Cellular Energy Balance in a Cell-Type Specific Manner
por: Pitman, Ryan T., et al.
Publicado: (2012)

Molecular cloning, sequence analysis and homology modeling of galE encoding UDP-galactose 4-epimerase of Aeromonas hydrophila
por: Agarwal, Shivani, et al.
Publicado: (2009)

Challenges and Opportunities for Cancer Vaccines in the Current NSCLC Clinical Scenario
por: Rodriguez, Pedro C, et al.
Publicado: (2013)

Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy
por: Heineman, David J., et al.
Publicado: (2017)

The Small RNA Landscape in NSCLC: Current Therapeutic Applications and Progresses
por: Ciccone, Giuseppe, et al.
Publicado: (2023)

Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects
por: Ryu, Rachel, et al.
Publicado: (2018)

NSCLC molecular testing in Central and Eastern European countries
por: Ryska, Ales, et al.
Publicado: (2018)

Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets
por: Bajbouj, Khuloud, et al.
Publicado: (2021)

Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
por: Zer, Alona, et al.
Publicado: (2014)

Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment
por: Li, Junnan, et al.
Publicado: (2020)

Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability
por: Tostes, Katiane, et al.
Publicado: (2023)

Reconstruction error based deep neural networks for coronary heart disease risk prediction
por: Amarbayasgalan, Tsatsral, et al.
Publicado: (2019)

Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome
por: Ding, Ruiwen, et al.
Publicado: (2022)

Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?
por: Remon, Jordi, et al.
Publicado: (2022)

Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report
por: Gerber, David E., et al.
Publicado: (2022)

RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC
por: Osta, Badi El, et al.
Publicado: (2020)

Molecular Mechanisms of Chemoresistance Induced by Cisplatin in NSCLC Cancer Therapy
por: Kryczka, Jolanta, et al.
Publicado: (2021)

Impact of the immune molecular profile of the tumor microenvironment on the prognosis of NSCLC
por: Ying, Hangjie, et al.
Publicado: (2023)

Brain metastases in ALK-positive NSCLC – time to adjust current treatment algorithms
por: Griesinger, Frank, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o5tu6r96qe91tlm363sujqb8js